/
We are an innovative commercial-stage healthcare company focused on shifting the paradigm in early cancer detection at population scale. We believe screening individuals for many types of cancer with a single test represents a significant opportunity to reduce the global burden of cancer.
The business is unprofitable at the operating level (-382.84% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 16.9% YoY with margins expanding 1360.2pp.
Negative free cash flow of -$300M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$156M
▲ +16.9% YoY
Net Income (TTM)
-$395M
▲ +79.9% YoY
Op. Margin
-349.40%
▲ +1360.2pp YoY
ROIC
-17.45%
▲ +50.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$292M
▲ +48.5% YoY
Op. Cash Flow (TTM)
-$291M
▲ +48.2% YoY
Net Debt
-$772M
Net Cash Position
Cash & Equiv.
$823M
3Y CAGR: +38.3%
Continue Research